Insys Therapeutics, Inc. - FORM S-1/A - EX-23.1 - CONSENT OF BDO USA, LLP - August 16, 2011

Attached files

file filename
S-1/A - AMENDMENT NO. 6 TO FORM S-1 - Insys Therapeutics, Inc.ds1a.htm
EX-10.5 - 2011 EQUITY INCENTIVE PLAN - Insys Therapeutics, Inc.dex105.htm
EX-10.6 - 2011 NON-EMPLOYEE DIRECTORS' STOCK AWARD PLAN - Insys Therapeutics, Inc.dex106.htm
EX-10.7 - 2011 EMPLOYEE STOCK PURCHASE PLAN - Insys Therapeutics, Inc.dex107.htm
EX-10.15 - SUPPLY AGREEMENT - Insys Therapeutics, Inc.dex1015.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Board of Directors and Stockholders

Insys Therapeutics, Inc.

Phoenix, Arizona

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 29, 2011, except for Note 13 which is as of July 14, 2011, relating to the consolidated financial statements of Insys Therapeutics, Inc., which is contained in that Prospectus.

We also hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated July 9, 2010, relating to the financial statements of NeoPharm, Inc., which also is contained in that Prospectus. Our report contains an explanatory paragraph regarding NeoPharm’s ability to continue as a going concern.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

/s/ BDO USA, LLP

Chicago, Illinois

August 16, 2011

Insys Therapeutics, Inc. Reports